logo
Forget a Takeover From Autodesk, PTC Is a Great Stock to Buy Anyway. Here's Why.

Forget a Takeover From Autodesk, PTC Is a Great Stock to Buy Anyway. Here's Why.

Yahoo15 hours ago
Key Points
A deal between Autodesk and PTC would have made good strategic sense.
The industrial software space is rapidly consolidating as the creation of digital threads and loops using data generated by software increases.
PTC's solutions lie at the heart of the adoption of digital technology in manufacturing.
10 stocks we like better than PTC ›
PTC (NASDAQ: PTC) investors were treated to a flurry of excitement in July as, according to reports, its larger peer Autodesk (NASDAQ: ADSK) took a serious look at acquiring the company only to appear to back off any such large undertakings by issuing a regulatory filing stating it was "allocating capital to organic investment, targeted and tuck-in acquisitions." Is the fun over, or are there more surprises to come?
PTC doesn't need Autodesk
The market had no doubt about its opinion on the speculation. Autodesk shares tumbled on the day Bloomberg discussed the potential bid, while PTC stock naturally soared. This is somewhat common in such situations, and is often driven by hedge funds engaging in so-called merger arbitrage. Hedge funds often look to sell shares in the acquiring company short while buying shares in the target company, and then make money when the spread between the two stocks closes when the deal is completed.
However, the interesting thing about the price action is that Autodesk's stock has somewhat recovered after the SEC filing was issued on July 14, but PTC's stock has remained relatively high.
Perhaps I've been spending too much time with the Oracle at Delphi, but it looks like the market is asking the question of "who's next to try and buy PTC?"
Why PTC is a highly attractive asset
It's a valid question, not least because there's been significant consolidation in the industrial software space over the last year. For example, German industrial and software giant Siemens bought Altair Engineering for $10 billion earlier this year to add Altair's strength in simulation and analysis software (computer-aided engineering, or CAE) to its core product lifecycle management (PLM), computer-aided design (CAD), and electronic design automation (EDA) strengths.
Not to be outdone, Synopsys (the market-leading EDA company) recently completed the acquisition of CAE company, and Altair rival, Ansys.
At which point readers are no doubt tired of the acronyms and wondering what it all means to PTC investors.
Why PTC can be part of the industrial software consolidation
A combination of Autodesk and PTC makes obvious sense, as it marries Autodesk's leadership in CAD with PTC's expertise in PLM to create an American champion better able to compete with France's Dassault Systèmes and Germany's Siemens. The two Europeans are leading players in the CAD/PLM/CAE space.
It's not just about adding acronyms; it's a reflection of the increasingly important interaction between design (CAD) and the digital management of a product through PLM, CAE, in the so-called digital loop.
For example, CAE modeling data can be fed back into PLM, and actionable conclusions can be drawn from it that lead to adjustments in a product's design using CAD, such as improving factory productivity or enhancing a product's reliability and quality.
As such, even if Autodesk/PTC is off the table, a larger software company looking to enter the industrial space can be interested, and there's always the possibility that an automation company -- like PTC's partner and former stakeholder, Rockwell Automation, or, thinking longer-term, Honeywell (not least as Honeywell Automation will be a separate company in future) or Emerson Electric (a company focusing on automation and industrial software) -- might consider making a move.
PTC is an excellent buy anyway
In any case, PTC doesn't need takeover speculation to be an attractive stock. Despite headwinds in its industrial end markets, the company has consistently generated double-digit growth in its annual run rate of software subscriptions. Moreover, it's likely to continue growing in the future as customer adoption of digital technology increases and the volume of valuable data created expands (through the use of digital twins, CAE, service lifecycle management software, etc.).
All of that data needs a hub and a repository, which is where PLM comes in. As such, PTC's solutions are an integral part of the modern manufacturing world. With Wall Street expecting ARR improvement to drop into double-digit free cash flow growth for the foreseeable future, PTC is an excellent option for a diversified growth portfolio, whether it receives a bid or not.
Should you buy stock in PTC right now?
Before you buy stock in PTC, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and PTC wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!*
Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 21, 2025
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Autodesk, Emerson Electric, PTC, Rockwell Automation, and Synopsys. The Motley Fool recommends Dassault Systèmes Se. The Motley Fool has a disclosure policy.
Forget a Takeover From Autodesk, PTC Is a Great Stock to Buy Anyway. Here's Why. was originally published by The Motley Fool
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Upland Software Announces the Successful Completion of Debt Refinancing
Upland Software Announces the Successful Completion of Debt Refinancing

Business Wire

timea few seconds ago

  • Business Wire

Upland Software Announces the Successful Completion of Debt Refinancing

AUSTIN, Texas--(BUSINESS WIRE)--Upland Software, Inc. (Nasdaq: UPLD) (the 'Company' or 'Upland Software'), a leader in AI-powered knowledge and content management software, today announced that it has entered into an agreement with private credit direct lender Sound Point Capital to refinance its existing debt with a new $240 million, six-year term loan, extending the maturity of its debt to 2031. The new credit agreement also includes a $30 million revolving credit facility, further enhancing the Company's financial liquidity. 'We're pleased to complete this new credit facility with Sound Point Capital, their speed and certainty throughout this process was a differentiator,' said Jack McDonald, Chief Executive Officer and Chairman of Upland Software. 'This refinancing enhances our financial flexibility, allowing us to invest further in our AI-powered knowledge and content management software solutions and drive long-term value for our customers and shareholders.' 'Sound Point Capital's one-stop lending platform was the optimal solution for Upland Software's next phase of growth and we're excited to support management and HGGC in their vision,' said Andrew Eversfield, Co-Head of Sound Point Direct Lending. Morrison & Foerster LLP acted as legal advisor to Upland Software, and Paul Hastings LLP acted as legal advisor to Sound Point Capital. About Upland Software Upland Software (Nasdaq: UPLD) is a leader in AI-powered knowledge and content management software. Our solutions help enterprises unlock critical knowledge, automate content workflows, and drive measurable ROI—enhancing customer and employee experiences while supporting regulatory compliance. More than 1,100 enterprise customers rely on Upland Software to solve complex challenges and provide a trusted path for AI adoption. For more information, visit About HGGC HGGC is a values-driven, partnership-focused private investment firm. The firm's ecosystem of investors, operators, and professionals are united by the shared mission to develop leading enterprises and build long term value together. HGGC invests in technology, business services, financial services and consumer enterprises generally valued between $200M - $1.5B+. The firm is based in Palo Alto, CA and manages over $8 billion in cumulative capital commitments. For more information, visit About Sound Point Capital Sound Point Capital is an alternative asset management firm founded in 2008 with particular expertise in credit strategies. Based in New York, with offices in London, Connecticut, Florida and California, the firm manages money on behalf of institutional investors including top-tier pensions, foundations, insurance companies, wealth management firms and family offices. Sound Point's strategies span the spectrum of liquid and illiquid credit alternatives and include funds and managed accounts focused on leveraged loans, special situations, distressed debt, structured credit, direct lending and commercial real estate. Sound Point currently manages $43+ billion of assets and was founded by Stephen J. Ketchum, who is the controlling shareholder. Five principals of Stone Point Capital LLC, as well as Blue Owl GP Stakes, a division of Blue Owl Capital Inc. [NYSE: OWL], and Assured Guaranty Ltd, through one or more subsidiaries, are strategic investors in our business. For more information, visit The statements and opinions presented above are endorsements provided by an executive of Upland Software. Upland Software is not a client of Sound Point or an investor in private funds managed by Sound Point. Sound Point has not provided any cash or non-cash compensation for the use of these statements. Sound Point's commercial relationship with Upland creates a conflict of interest since the executive has an incentive to make positive statements about Sound Point and its experience to maintain the goodwill with Sound Point. These statements describe the executive's experience with Sound Point and/or its supervised persons and may not be representative of the experience of others. Provided for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. All investing involves risk, including the risk of a total loss.

Will AGI Take Nvidia Stock To $300?
Will AGI Take Nvidia Stock To $300?

Forbes

timea minute ago

  • Forbes

Will AGI Take Nvidia Stock To $300?

Could Nvidia stock (NASDAQ:NVDA) reach $300 in the next two years? There's a strong possibility. How? Consider this, just about three months ago, at the end of April 2025, Nvidia stock was trading at around $95 levels and presently trades at close to $174 per share. The stock is also up roughly 4x over the past two years. Let's look at valuations. Nvidia stock trades at about 40x consensus FY'26 earnings. Is this pricey?Not really. Especially if you consider the company's steadily expanding earnings, the long-growth runway for the artificial intelligence market, and Nvidia's formidable lead in the accelerated computing market. And if AGI (Artificial General Intelligence) becomes even partially realized over the next few years, the demand for high-performance computing could soar exponentially. In the scenario below, we use Nvidia's revenues, profitability, and valuation multiples to demonstrate a potential path to a $300 stock price. Nvidia CEO Jensen Huang delivers a keynote address at the Consumer Electronics Show (CES) in Las ... More Vegas, Nevada on January 6, 2025. Gadgets, robots and vehicles imbued with artificial intelligence will once again vie for attention at the Consumer Electronics Show, as vendors behind the scenes will seek ways to deal with tariffs threatened by US President-elect Donald Trump. The annual Consumer Electronics Show (CES) opens formally in Las Vegas on January 7, 2025, but preceding days are packed with product announcements. (Photo by Patrick T. Fallon / AFP) (Photo by PATRICK T. FALLON/AFP via Getty Images) More Demanding Workloads, AGI Can Drive Revenue Nvidia's revenues grew by almost 2x over the last 12 months, while posting an average annual growth rate of about 69% over the last three years, and the momentum can hold up. If Nvidia grows its sales at an average annual rate of over 60% for the next two years - its revenues could move from around $131 billion in FY'25 to around $334 billion by FY'27 or over 2.5x. There are several trends that could drive continued growth. While the initial AI models deployed by the likes of OpenAI in 2022 were largely text-based, models are increasingly multimodal, working with speech, images, video, and 3D calling for higher computing power and a larger number of GPU shipments. Besides this, Nvidia recently indicated that it received assurances from the Trump administration allowing it to resume sales of its H20 artificial-intelligence chip to China after facing a ban around April. This marks a significant win for the company, as it preserves access to a major and fast-growing AI market. More importantly, AI is expected to evolve from its current form - writing text, generating images - to more general intelligence. While the timeline is not certain, the goal is to get AI to reason, plan, learn new tasks without retraining. Artificial General Intelligence (AGI) could conduct scientific research, generate novel insights, or design entire products on its own. This could unlock breakthroughs and innovations across industries and some models suggest this could push global GDP growth from low single digits to over 20% annually. ((The Economist)) As the world moves closer to AGI, Nvidia could stands to benefit enormously. AGI systems are expected to require massive computational resources to train and run, considerably exceeding today's models, and Nvidia's GPUs are currently the industry standard for powering such workloads. AGI could not just be the next industrial revolution, it could be much bigger and Nvidia's chips could be right at the heart of it. Now the stock markets are often myopic and tend to extrapolate short-term trends for the long run. In Nvidia's case, the assumption is that demand growth and pricing power will hold up and profits will remain sizable as the generative AI wave advances. However, there are multiple risks and there remains a real possibility that the stock could see a sizable correction. We detail this possibility in our analysis of Nvidia Stock To Crash In 2025? Indeed we believe this broad range of upside and downside potential represents a simple fact: Nvidia is a volatile stock. Net Margins Will Remain Thick Combine this solid revenue growth with the fact that Nvidia's margins (net income, or profits after all expenses and taxes, calculated as a percent of revenues) are on an improving trajectory - they grew from levels of about 25% in FY'19 to over 51% in FY'25 as the company witnessed better economies of scale and a more favorable product mix skewed toward complex data center products. Software-related sales are also trending higher. We can assume that margins will remain flat at current levels as Nvidia's launch of pricier higher-end products such as the latest Blackwell chips are offset by potentially higher costs and competition in the lower-end of the market from the likes of AMD. With margins remaining flat and revenue rising 2.5x, we could see earnings rise 2.5x. Looking for an alternative AI play: Could AI contender AMD see a lift ahead of earnings? Strong Results Could Mean Earnings Multiples Hold Up Now, if earnings grow 2.5x, the PE multiple will shrink by 2.5x to levels of about 16x, assuming the stock price stays the same. But that's exactly what Nvidia investors are betting won't happen. If earnings expand 2.5x over the next few years, instead of the PE shrinking from a figure around 40x now to about 16x, a scenario where the PE metric stays at about 28x looks quite likely. For perspective, Apple - a company that is growing at low single-digits - trades at 30x. This would make the growth of Nvidia's stock by 1.7x within the next two years or so a real possibility, translating into a price of over $300 per share. What about the time horizon for this high-return scenario? In practice, it won't make much difference whether it takes two years or three, as long as Nvidia is on this revenue expansion trajectory, with margins holding up, the stock price could respond similarly. While Nvidia stock could have massive upside, it comes with risks and considerable volatility. On the other hand, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

Yahoo

time29 minutes ago

  • Yahoo

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. Multipotency refers to a flexible cellular state in which a cell has the potential to differentiate into multiple specialized cell types, depending on the environmental conditions or stimuli it encounters. While stem cells have garnered the most attention on being multipotent, fibroblasts are also considered multipotent and can be directly differentiated into many cell types including chondrocytes, osteocytes, hepatocytes and cardiomyocytes. This patent application broadly relates to methods for generating multipotent cells directly from fibroblasts found in human donor tissues. 'This method provides us with the ability to obtain larger quantities of stable and easily scalable multipotent cells from donor-derived fibroblasts for use in clinical applications,' said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. 'Multipotent fibroblasts also show enhanced ability to form 3D spheroid structures, further expanding their potential across a range of therapeutic and drug development areas.' Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics, said, 'By enabling the generation of stable, multipotent cells directly from donor tissue, this innovation addresses long-standing challenges in the field and opens new possibilities for scalable, regenerative treatments.' For more information, please visit FibroBiologics' website or email FibroBiologics at info@ Cautionary Statement Regarding Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of multipotent fibroblasts across a range of therapeutic and drug development areas and new possibilities for scalable, regenerative treatments. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit General Inquiries:info@ Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347) in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store